All In Biotech

Drug Trial Radar · NCT06072131

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 504 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

504

Planned (sponsor's estimate)

Start

Oct 4, 2023

Primary completion

Jul 2030

Study completion Nov 2030

Sponsor

Lead sponsor
Acrotech Biopharma Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-CHOP or Fol-COP) or 1 active comparator treatment group (CHOP). Patients will be treated for up to 6 cycles. The primary objective is to compare the Progression Free Survival of patients with newly diagnosed PTCL treated for up to 6 cycles with Beleodaq (belinostat) in combination with CHOP (Bel-CHOP) or Folotyn (pralatrexate injection) in combination with COP (Fol-COP) to CHOP alone.

Conditions

  • Peripheral T Cell Lymphoma

Interventions

  • Belinostat InjectionDrug

    Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle

  • Pralatrexate InjectionDrug

    Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle

  • CHOPDrug

    CHOP is the comparator arm

  • COPDrug

    COP is given in combination with Pralatrexate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 4.5 years

Locations

58 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco Fresno

    Clovis, California

  • University of California, Los Angeles Hem/ Onc Clinical Research Unit, Suite 600

    Santa Monica, California

  • University of Colorado School of Medicine

    Aurora, Colorado

  • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System Memorial Cancer Institute

    Pembroke Pines, Florida

  • Norton Cancer Institute

    Louisville, Kentucky

  • Henry Ford Health System

    Detroit, Michigan

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Ohio Health Research Institute

    Columbus, Ohio

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • Baylor Scott & White Medical Center - Temple

    Temple, Texas

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Universitatsmedizin Gottingen

    Göttingen, Germany

  • Universitaetsklinikum Halle (Saale)

    Halle, Germany

  • Semmelweis Egyetem

    Budapest, Hungary

  • National Institute of Oncology

    Budapest, Hungary

  • Belgyogyaszati Klinika es Kardiologiai Kozpont

    Szeged, Hungary

  • University of Debrecen Clinical Center

    Debrecen, Nagyerdei Krt. 98, Hungary

  • Andras Josa University Teaching Hospital

    Nyíregyháza, Szent Istvan Utca, Hungary

  • Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo

    Alessandria, Italy

  • Ospedale Policlinico San Martino, IRCCS

    Genova, Italy

  • Azienda Ospedaliera Universitaria di Parma

    Parma, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Azienda USL di Ravenna

    Ravenna, Italy

  • Azienda Ospedaliera Cardinale Giovanni Panico

    Tricase, Apulia, Italy

  • University of Milano Bicocca

    Milan, Bicocca, Italy

  • Servizio Sanitario Regionale Emilia-Romagna-Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" Srl (IRST)

    Meldola, Province Of Forlì-Cesena, Italy

  • Policlinico GB Rossi Borgo Roma

    Borgo Roma, Verona, Italy

  • Pratia MCM Krakow

    Krakow, Poland

  • Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

    Warsaw, Poland

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

    Lodz, Łódź Voivodeship, Poland

  • University Hospital in Wroclaw

    Wroclaw, Wroclaw, Poland

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Inje University Busan Paik Hospital

    Busan, Busanjin District, South Korea

  • Ajou University Hospital

    Suwon, Gyenoggi-do, South Korea

  • The Catholic University of Korea - St. Vincents Hospital

    Suwon, Gyeonggi-do, South Korea

  • Yeungnam University Medical Center

    Daegu, Nam-gu, South Korea

  • Severance hospital, Yonsei University

    Sinchon-dong, Seoul, South Korea

  • Asan Medical Center

    Songpa-dong, Seoul, South Korea

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.